According to our (Global Info Research) latest study, the global Shengagliptin Phosphate Tablets market size was valued at US$ 12.86 million in 2025 and is forecast to a readjusted size of US$ 59.03 million by 2032 with a CAGR of 12.5% during review period.
Sentagliptin Phosphate Tablets are a Class 1 innovative oral hypoglycemic drug independently developed in China, belonging to high‑selectivity DPP‑4 inhibitors. By inhibiting the activity of dipeptidyl peptidase 4, the drug delays the degradation of incretins in the human body and bidirectionally regulates the secretion of insulin and glucagon, so as to steadily control blood glucose levels. It exerts a mild hypoglycemic effect with a low risk of hypoglycemia and favorable medication safety and tolerance. It is mainly applied to improve blood glucose control in adult patients with type 2 diabetes, and can be used as monotherapy or in combination with hypoglycemic agents such as metformin. As a newly launched domestic innovative metabolic drug, Sentagliptin Phosphate Tablets diversify the clinical treatment options for type 2 diabetes in China and meet the long‑term management needs of chronic diseases. Supported by clinical promotion and favorable medical policies, it enjoys promising development prospects in the hypoglycemic drug market.In 2025, global Sentagliptin Phosphate Tablets production reached approximately 1.6 million bottles.
Sentagliptin Phosphate Tablets are a Class 1 innovative DPP-4 inhibitor independently developed in China. Relying on excellent clinical efficacy and safety, it has outstanding market competitiveness in the treatment of type 2 diabetes. As a new generation of highly selective preparation, the drug features an extremely low risk of hypoglycemia and good tolerance. It meets the clinical needs of elderly patients and those with combined high-risk factors. Meanwhile, it supports flexible combined medication regimens and can be used synergistically with a variety of hypoglycemic drugs, expanding clinical application scenarios. Supported by the National Major New Drug Creation Special Project, it enjoys a long patent protection period and a stable market life cycle. At present, the domestic DPP-4 inhibitor market faces fierce competition with coexisting imported original drugs and domestic generic drugs. As an innovative drug with differentiated advantages, Sentagliptin Phosphate Tablets is expected to gradually increase its market share through medical insurance access, clinical academic promotion and grassroots market penetration. With the growing demand for chronic disease management of diabetes and the continuous release of policy dividends for innovative drugs, this product will further enrich clinical treatment options, accelerate the import substitution of domestic innovative hypoglycemic drugs, and present remarkable long-term market development potential.
This report is a detailed and comprehensive analysis for global Shengagliptin Phosphate Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Shengagliptin Phosphate Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Shengagliptin Phosphate Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Shengagliptin Phosphate Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Shengagliptin Phosphate Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Shengagliptin Phosphate Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Shengagliptin Phosphate Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cgenetech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Shengagliptin Phosphate Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
50mg
100mg
Market segment by Dosage Form
Conventional Tablets
Immediate-release Oral Tablets
Market segment by Combination Therapy
Combined With Metformin
Combined With Sulfonylureas
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Application
Type 2 Diabetes Treatment
Blood Glucose Control
Chronic Disease Management
Others
Major players covered
Cgenetech
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Shengagliptin Phosphate Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Shengagliptin Phosphate Tablets, with price, sales quantity, revenue, and global market share of Shengagliptin Phosphate Tablets from 2021 to 2026.
Chapter 3, the Shengagliptin Phosphate Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Shengagliptin Phosphate Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Shengagliptin Phosphate Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Shengagliptin Phosphate Tablets.
Chapter 14 and 15, to describe Shengagliptin Phosphate Tablets sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Shengagliptin Phosphate Tablets. Industry analysis & Market Report on Shengagliptin Phosphate Tablets is a syndicated market report, published as Global Shengagliptin Phosphate Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Shengagliptin Phosphate Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.